Testing Status of Acronycine C01536

 

CASRN: 7008-42-6

Formula: C20-H19-N-O3

Synonyms/Common Names

  • 3,12-Dihydro-6-methoxy-3,3,12-trimethyl-7H-pyrano(2,3-c)acridin-7-one

Known Uses

Anticancer drug

Chemical Properties

Toxicity Effects (HSDB)

Short-Term Toxicity

  • 14-Day (Intraperitoneal Injection)  (C01536)  Completed 
    • Rats: Sprague Dawley; Mice: B6C3F1
  • 13-Week (Intraperitoneal Injection)  (C01536)  Completed 
    • Rats: Sprague Dawley; Mice: B6C3F1
    • Dose: MR: 0, 1.5, 30, M: 0, 2.5, 50 MG/KG/10 PER GROUP.

Long-Term Carcinogenicity

  • 2-Year (Intraperitoneal Injection)  (C01536)  Report Complete 
    • TR-049 (NIH Number: 78-849)  (Peer Review Approval 03/07/1978A )
      Bioassay of Acronycine for Possible Carcinogenicity (CASRN 7008-42-6)
    • Rats: Sprague Dawley; Mice: B6C3F1
    • Carcinogenesis Results
      • Male Rats Positive 
      • Female Rats Positive 
      • Male Mice Inadequate Study 
      • Female Mice Inadequate Study 
    • Dose: R: 0, 3.75, 7.5, 15, M: 0, 2, 6, 12.5, 25 MG/KG/35 PER GROUP.